ahlam1399
03-24-2016, 03:16 PM
Portola?s long-acting blood thinner misses main goal in study
(Reuters) - Portola Pharmaceuticals Inc said late-stage data showed its oral anticoagulant was **t superior to an injectable standard therapy in preventing blood clots in acutely ill patients.
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2.img (http://da.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/ach.img (http://adchoice.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/ach.htm)http://pi.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2t.imghttp://pi2.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e7c3d8f/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xOLux8b3y2Y:QAh4t7rEELY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xOLux8b3y2Y:QAh4t7rEELY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/xOLux8b3y2Y
(Reuters) - Portola Pharmaceuticals Inc said late-stage data showed its oral anticoagulant was **t superior to an injectable standard therapy in preventing blood clots in acutely ill patients.
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2.img (http://da.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/ach.img (http://adchoice.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/ach.htm)http://pi.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2t.imghttp://pi2.feedsportal.com/r/247395839150/u/49/f/654207/c/35217/s/4e7c3d8f/sc/14/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e7c3d8f/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xOLux8b3y2Y:QAh4t7rEELY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xOLux8b3y2Y:QAh4t7rEELY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=xOLux8b3y2Y:QAh4t7rEELY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/xOLux8b3y2Y